Kyn Biosciences Inc. is a seed and series A-stage investment group that leverages expertise in technology, finance, governance, operations, and regulatory frameworks to identify global investment opportunities within the biosciences domain.
Kyn’s areas of interest include, but are not limited to, novel extraction methodologies, pharmaceutical applications, delivery systems, experimental or research platforms, and clinical trials.
We’re always looking for new opportunities, and welcome inbound pitches.
OUR APPROACH
Every entrepreneur, business, and potential investment is unique. We evaluate each investment for its long-term market opportunity, synergistic-fit relative to our existing portfolio, and a range of proprietary qualitative and quantitative metrics.
We pride ourselves on our team’s cumulative broad-domain of experience and our corresponding network of relationships. Even if Kyn does not participate in an investment opportunity, we provide each entrepreneur courteous and respectful feedback, and do our best to point them in the right direction.
By intentionally fostering community and creating goodwill, a Kyn investment brings more than just a cheque, we bring the relationships that, ideally, create business opportunity, future capital introductions, and accelerate value creation.
Prior investments
-
Translational Life Sciences
With its renowned team of scientists, state-of-the-art laboratory and unique testing models, Translational Life Sciences has the ability to develop novel therapies for unlimited applications in critical need areas related to mental health.
-
Elevated Signals
A state-of-the-art production management software platform for licensed cannabis producers and processors.
-
Pangenomic
Helping more people discover plant-based health remedies and giving them greater personal control over mental health treatments.
OUR HISTORY
Kyn Biosciences was founded in 2018 as GrowTech Labs with the mission of investing in early stage, pre-legalization plant medicine products and services.
Since the original formation of GrowTech Labs, the plant medicine landscape has radically changed. Cannabis is fully legalized and commercially available throughout every province and territory, years of research and development have taken place, and Canada is positioned as a world leader in the space.
Plant medicines derived from illicit substances have been decriminalized in British Columbia, where criminal penalties have been removed for people who possess a small amount of certain illicit substances for personal use. Two US states and several US cities have also decriminalized the use of psilocybin.
GrowTech Lab’s rebranding to Kyn Biosciences in 2023 reflects the increased maturity of the plant-medicine based products and services and the broader application of plant medicines within society.
BC Craft Farmers Co-op
British Columbia is world renowned for its cannabis culture and the quality of cannabis produced within the province. GrowTech Labs began the process of developing a co-op under the BC Cooperative Association Act in November 2019 to give this group, transitioning into legalization, a unified voice.
GrowTech Labs funded the development of a working group of sector leaders and experienced co-op professionals to create a provincial engagement plan, transparent governance structure, and application to incorporate the BC Craft Farmers Co-Op within the provincial Co-operative Association Act.
The co-op is now incorporated and self-governed by cultivators, processors and retailers.
OUR TEAM
The Kyn team is composed of individuals with a unique set of backgrounds. Our team profile is here.